Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05413135 · ClinicalTrials.gov registry record · Phase 2

Study of ARO-APOC3 in Adults With Dyslipidemia

A Phase 2 study of Dyslipidemias, sponsored by Arrowhead Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
418
Enrollment target
20
Study locations

NCT05413135 is a Phase 2 study of Dyslipidemias that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 418 participants, above the 218-participant average among 28 other Dyslipidemias trials with a reported enrollment target (92% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05413135, a Phase 2 study of Dyslipidemias, has completed, sponsored by Arrowhead Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
418 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.

Conditions Studied

Dyslipidemias

Interventions

  • DRUG ARO-APOC3

Study Locations (20)

Florida

  • Clincal Research Site 4 - Boca Raton
  • Clinical Research Site 5 - Fort Lauderdale
  • Clinical Research Site 8 - Miami
  • Clinical Research Site 6 - Miami
  • Clinical Research Site 9 - Miami Springs
  • Clinical Research Site 10 - Pembroke Pines
  • Clinical Research Site 11 - Port Orange

California

  • Clinical Research Site 1 - Beverly Hills
  • Clinical Research Site 2 - Northridge
  • Clinical Research Site 3 - Palm Springs

New York

  • Clinical Research Site 17 - Long Island City
  • Clinical Research Site 18 - New Windsor
  • Clinical Research Site 19 - New York

Georgia

  • Clinical Research Site 12 - Dunwoody

Minnesota

  • Clinical Research Site 13 - Minneapolis

Mississippi

  • Clinical Research Site 14 - Tupelo

Nebraska

  • Clinical Research Site 15 - Omaha

Nevada

  • Clinical Research Site 16 - Las Vegas

Trial Details

FieldValue
Enrollment Target 418 participants
Start Date 2022-07-07
Est. Completion 2025-09-18
Phase Phase 2

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05413135

The ClinicalTrials.gov registry entry for NCT05413135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 28 other Dyslipidemias trials with a reported enrollment target (92% higher). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 1 intervention - of which ARO-APOC3 is the first listed.

NCT05413135 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT05413135 about?

NCT05413135 is a clinical study titled "Study of ARO-APOC3 in Adults With Dyslipidemia". This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled p...

What is the current status of trial NCT05413135?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2022-07-07. Estimated completion is 2025-09-18.

What conditions does trial NCT05413135 study?

This clinical trial studies the following conditions: Dyslipidemias.

What interventions are being tested in trial NCT05413135?

The interventions under investigation include: ARO-APOC3 (DRUG).

Who is sponsoring clinical trial NCT05413135?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05413135 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Minnesota, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dyslipidemias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dyslipidemias

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.